Correlation Between HBA1c Level and Thickness of Both Macula and Choroid in Patients With Type 2 Diabetes Mellitus

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05778370
Collaborator
(none)
45
7.6

Study Details

Study Description

Brief Summary

Diabetic retinopathy (DR) is a frequent cause of visual impairment, and the leading cause of blindness in those of working age, but it develops silently along years, producing symptoms only in late stages.

Condition or Disease Intervention/Treatment Phase
  • Device: Swept Source Optical Coherence Tomography(Topcon DRI Triton)

Detailed Description

The risk of sight-threatening consequences can be reduced if the lesions are detected before irreversible damage to retinal function has developed .Patients with diabetes mellitus (DM) have many pathological changes in their macula as diabetic macular edema (DME), exudates, cysts, detachment and ischemia that cause impairment of vision.

DME is characterized by increased vascular permeability and deposition of hard exudates at the macula and can occur at any stage of DR. With the help of OCT, it is possible to quantify the macular thickness objectively and to follow the progression of DME quantitatively.

Currently, DME is classified as 'center involved' or 'non center involved' (referring to whether or not there is oedema i.e., CMT>250 μm at the fovea) based on OCT. Non-centre involved macular oedema is rarely symptomatic. However, as the oedema spreads to the central macula, patients usually experience progressive vision loss and treatment with anti-VEGF is recommended.

Also, DM can cause many pathological changes in the choroid as increased tortuosity, focal vascular dilatation, microaneurysms and nonperfused areas. Studies have analyzed choroidal thickness changes in DR using spectral domain optic coherence tomography. A number of studies have shown that choroidal thickness decreases as the diabetic retinopathy progresses.

Swept-source (SS) OCT is a variation of OCT that offers improvements in visualizing the vitreous, retina, and choroid at one image. The increased scan speeds, decreased signal attenuation, more comprehensive imaging, and deeper tissue penetration make SS-OCT ideal for capturing a wide range of views and studying structures below the retinal pigmented epithelium (RPE), especially the choroid.

Glycated haemoglobin (HbA1c) is measured primarily to identify the average plasma glucose concentration over prolonged periods and reflect the long-term control of hyperglycaemia. Higher levels of HbA1c increase the incidence of DME over a 10-year period in Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR). The Diabetes Control and Complication Trial (DCCT) and the UK Prospective Diabetic Study (UKPDS) both of which were randomized prospective studies showed that intensive glycaemic control and thus reduction of HbA1c levels are associated with a decrease in the rates of development and progression of DR and DME.

The use of HbA1c for the diagnosis of DM has been approved by the WHO based on a number of epidemiological studies showing that a threshold for increased prevalence of microvascular complications can be observed at HbA1c level of 6.5% .

Aim of the work To investigate the correlation between HbA1c levels in patients with type II diabetes mellitus on central macular thickness as well as central choroidal thickness using swept source optical coherence tomography.

Study Design

Study Type:
Observational
Anticipated Enrollment :
45 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Correlation Between HBA1c Level and Thickness of Both Macula and Choroid in Patients With Type 2 Diabetes Mellitus
Anticipated Study Start Date :
Apr 15, 2023
Anticipated Primary Completion Date :
Nov 15, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Group 1

will include 15 patients (30 eyes) of age matched non-diabetic candidates (control group)

Device: Swept Source Optical Coherence Tomography(Topcon DRI Triton)
Topcon DRI Triton

Group 2

will include 15 patients (30 eyes) of diabetic patients with good glycemic control (HbA1c ≤7%),

Device: Swept Source Optical Coherence Tomography(Topcon DRI Triton)
Topcon DRI Triton

Group 3

will include 15 patients (30 eyes) of diabetic patients with poor glycemic control (HbA1c <7% (

Device: Swept Source Optical Coherence Tomography(Topcon DRI Triton)
Topcon DRI Triton

Outcome Measures

Primary Outcome Measures

  1. Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus [baseline]

    Taking oct record for diabetic patients already know their HBA1c level ( done within 3 months max ) . Without follow up Findings will be compared controlled and non controlled group and with control group (normal people) To correlate if there's relavence between the Hba1c and macular thickness

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • • Patients with type II diabetes mellitus and their age above 30 years.

  • No history of any previous ocular surgery.

Exclusion Criteria:
  1. Unregulated arterial blood pressure, or cardiovascular disorder.

  2. Media opacity that affects posterior pole imaging by OCT

  3. Hyperopia of 4 diopters (D)

  4. Myopia of -6 D.

  5. Age related macular degeneration and other retinal or choroidal pathologies.

  6. Any history of previous eye surgery.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Chair: Mohamed S Saad, Prof, Assiut University
  • Study Director: Mohamed Sharaf-Eldin, Dr, Assiut University
  • Principal Investigator: Dalia M Ali, Dr, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Salma Gamal Nouby Mahmoud, Resident doctor at soad kafafi hospital, Assiut University
ClinicalTrials.gov Identifier:
NCT05778370
Other Study ID Numbers:
  • HBA1c and OCT Macula
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 21, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2023